Novo Nordisk has previously stated that semaglutide, the active ingredient in the diabetes treatment Ozempic and weight loss treatment Wegovy, significantly reduces the risk of complications, heart problems and death in people with type 2 diabetes and chronic kidney disease.

This has now been confirmed by studies published Friday at the European Renal Association meeting in Stockholm and in The New England Journal of Medicine, according to the New York Times. 

The study’s primary endpoint, presented by Novo Nordisk in March, of a 24% reduction in kidney damage including kidney failure, chronic kidney disease, and fatal kidney and circulatory events in patients with type 2 diabetes compared to placebo is repeated in Friday’s announcement. 

The secondary endpoints showed an 18% reduction in the risk of major cardiovascular events and a 20% reduction in the risk of all-cause mortality, according to the European Renal Association announcement. 

English edit: Catherine Brett